leadf
logo-loader
viewArcadia Biosciences Inc

Arcadia Biosciences enters into warrant-exercise agreement with institutional investor to raise $2.5 million

The money will help launch HB4 soybean, a drought-tolerant, herbicide-resistant seed solution developed via a joint venture (Verdeca) with Bioceres Crop Solutions

Arcadia Biosciences Inc - Arcadia Biosciences enters into warrant-exercise agreement with an institutional investor to raise $2.5 million to fund Verdeca joint venture with Bioceres Crop Solutions Corp
The funding will help expand HB4's acreage to potentially hundreds of thousands over the next crop cycle in anticipation of the launch

Arcadia Biosciences Inc (NASDAQ:RKDA) said Monday it has entered into a warrant-exercise agreement with an institutional investor to raise $2.5 million.

Through Verdeca, a joint venture between the company and Bioceres Crop Solutions Corp (NYSEAMERICAN: BIOX), Arcadia BioSciences said it intends to use proceeds from the warrant exercise to support the launch of Verdeca's HB4 soybean, a drought-tolerant, herbicide-resistant seed solution available for soybean.

Under the agreement, the institutional investor will exercise certain existing warrants to purchase up to an aggregate of 641,416 shares of common stock at a reduced price of $3.975 per share. 

READ: Arcadia Biosciences wins foundational Australian patent covering herbicide tolerance in wheat

Additionally, California-based Arcadia Biosciences said it has agreed to issue to the investor new unregistered warrants to purchase up to an aggregate of 641,416 shares of common shares at $3.85 each and with an exercise period of five and one-half years from the date of issuance. 

The closing of the transaction is expected to occur on or about July 8, subject to the satisfaction of customary closing conditions.

"The exercise of these warrants by our current investor provides necessary funding to begin expanding our HB4 acreage to potentially hundreds of thousands over the next crop cycle in anticipation of launch," said Arcadia Biosciences CEO Matt Plavan.

"Through Verdeca, we are also increasing our investment in breeding and new market development activities to access incremental geographies including Brazil and the US, as well as preparing for eventual approval in China."

HC Wainwright & Co is acting as exclusive placement agent for the offering.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Arcadia Biosciences Inc

Price: 3.33 USD

NASDAQ:RKDA
Market: NASDAQ
Market Cap: $35.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arcadia Biosciences Inc named herein, including the promotion by the Company of Arcadia Biosciences Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Kazia Therapeutics moves into operational phase of pivotal study for...

Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott soon after announcing they've executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to begin participation in the GBM AGILE pivotal study in glioblastoma. The study is set to open...

1 hour, 44 minutes ago

2 min read